about
sameAs
The Down syndrome critical region protein TTC3 inhibits neuronal differentiation via RhoA and Citron kinasep130Cas mediates the transforming properties of the anaplastic lymphoma kinaseKRAS-driven lung adenocarcinoma: combined DDR1/Notch inhibition as an effective therapyInvolvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growthThe anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation.MT1-MMP is required for myeloid cell fusion via regulation of Rac1 signalingIncreased Rrm2 gene dosage reduces fragile site breakage and prolongs survival of ATR mutant mice.Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastomaHuman Wrnip1 is localized in replication factories in a ubiquitin-binding zinc finger-dependent manner.Therapeutic inhibition of TRF1 impairs the growth of p53-deficient K-RasG12V-induced lung cancer by induction of telomeric DNA damageNegative feedback regulation of Rac in leukocytes from mice expressing a constitutively active phosphatidylinositol 3-kinase gamma.Redundant and nonredundant roles for Cdc42 and Rac1 in lymphomas developed in NPM-ALK transgenic mice.Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2/SIN3a deacetylating complex.The anaplastic lymphoma kinase in the pathogenesis of cancer.Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cellsCombined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors.Lentiviral-based approach for the validation of cancer therapeutic targets in vivo.Modeling lung cancer evolution and preclinical response by orthotopic mouse allografts.ALK-dependent control of hypoxia-inducible factors mediates tumor growth and metastasis.Back to the bench? MEK and ERK inhibitors for the treatment of KRAS mutant lung adenocarcinoma.PPP4R2 regulates neuronal cell differentiation and survival, functionally cooperating with SMN.Expression of IFNγR2 mutated in a dileucine internalization motif reinstates IFNγ signaling and apoptosis in human T lymphocytes.The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination.Simple and rapid in vivo generation of chromosomal rearrangements using CRISPR/Cas9 technology.Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas.NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells.Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency.A putative role for Discoidin Domain Receptor 1 in cancer chemoresistance.The Tyrosine Phosphatase Shp2 Interacts with NPM-ALK and Regulates Anaplastic Lymphoma Cell Growth and MigrationWiskott-Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma.Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung CancerAn integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancerImpact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer
P50
Q24305142-6734F77A-2692-4476-9B37-379C6EE458E6Q24315788-707A8230-04FD-4934-803E-1244709C1800Q28069764-EA3154C4-4019-41D5-B9E4-D7EF7DE4C2BAQ30156817-EFF64012-6876-4C11-9C62-23288B434959Q30484934-D50AB037-46EF-461D-8898-9AE0199E56A5Q33657191-9B212E3F-DC7E-4258-95EB-51635A0674CFQ35293714-C3385E15-7FE1-439E-9D73-046338818FF0Q35623435-3E79BB93-3D54-448A-BB07-2466A578A054Q35676889-B263120D-F9D8-4E97-B3CE-3541307B3CF9Q35904248-A1DA2563-5282-4BC3-A4A4-84C86AB44BBCQ35950260-BD6449B0-4C86-4407-9E8E-045C5C98F34AQ36675069-6A5CAABF-0D48-44C3-B1B2-DCAB028CB3B0Q36801093-FEFA961F-DAB2-4EF5-BA30-2DAF93A8409BQ37039605-B8E7310A-861B-44EA-BE16-CF810ECA41F0Q38716411-F7B22CD3-0845-4936-97DD-AD04FBB9ED0BQ38795629-DE836607-08C7-46AA-9461-C4F0392D9B9AQ38831440-663F28BE-37AE-4995-A9B0-45A9D1F76C10Q38948189-417F4CA8-4937-4E8A-BC35-9342F4111252Q38956964-6B0ECF5E-0C7A-46F6-B099-54993551CDF5Q38959374-55F01492-DAD2-42FB-8519-B140EAC0BE44Q39336289-D2E68ECE-2138-456B-8B0E-6DC6411CE97CQ39353583-58374F79-E215-4177-82E4-6DA6AB65B9A7Q39667574-F691FA0D-6C0C-4723-B473-D62E939EC01CQ39983708-BB0C64BB-54F3-47C3-9872-7C842A511DCFQ41747565-A5D4BEE0-EC67-4232-9847-6B33E1CE7C65Q42004966-DF9DFA07-FD0E-44E4-9C7E-F090572729E9Q42052786-318756E5-6426-465B-9ECC-BA55ED12BFA1Q42199612-3AE66B5D-FD88-4F74-9642-F40148DB0214Q53704648-D030A0AB-EFBB-4355-8F21-98D569CBF282Q58065800-5BB80E6B-7382-414B-A5C2-894796E11FD0Q64994137-F371BBED-E476-4E33-9095-6033CB532CA9Q89266805-EB90C808-9C54-4E80-8F0A-46EEC4400232Q91023495-D593425C-2EB8-43BE-A8EA-993942D9438CQ91492555-93C799B9-4A1B-4276-9F22-F9BA995F209A
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Chiara Ambrogio
@ast
Chiara Ambrogio
@en
Chiara Ambrogio
@es
Chiara Ambrogio
@nl
Chiara Ambrogio
@sl
type
label
Chiara Ambrogio
@ast
Chiara Ambrogio
@en
Chiara Ambrogio
@es
Chiara Ambrogio
@nl
Chiara Ambrogio
@sl
prefLabel
Chiara Ambrogio
@ast
Chiara Ambrogio
@en
Chiara Ambrogio
@es
Chiara Ambrogio
@nl
Chiara Ambrogio
@sl
P106
P21
P31
P496
0000-0003-4122-701X
P569
2000-01-01T00:00:00Z